Novartis names new US pharma chief

Share this article:
Novartis confirmed in published reports today that it has appointed Ludwig Hantson to head its US pharmaceuticals business. 

Hantson reports to Joe Jimenez, CEO of the Basel, Switzerland-based company's pharmaceutical business. Hantson replaces Alex Gorsky, who announced he was leaving Novartis in February. 
Hantson most recently served as head of Novartis' specialty pharmaceuticals unit in the US, where he has worked since December 2006. 

Novartis also said Paulo Costa, president and CEO of Novartis' US unit, will retire June 30 and be replaced by Gary Rosenthal. Rosenthal is currently CFO of the US pharmaceuticals business. 
Share this article:

Email Newsletters

More in News

FDA kind of OKs Lilly/BI's Lantus look-alike

FDA kind of OKs Lilly/BI's Lantus look-alike

Sanofi's patent lawsuit triggered the tentative approval of the Lilly-BI Lantus competitor.

GSK relaunches COPD.com

GSK relaunches COPD.com

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.

Six things for pharma marketers to know: Tuesday, August 19

Six things for pharma marketers to know: Tuesday, ...

Lilly/BI receives tentative approval for insulin biosimilar; Ebola death rate hits new high; LaMattina sounds off on Pfizer's oncology efforts; art therapy becoming the norm in hospitals.